LITS
Lite Strategy, Inc.Lite Strategy, Inc. a clinical-stage pharmaceutical company, focuses on the development of novel and differentiated therapies for the treatment of cancer. The company was formerly known as MEI Pharma, Inc. and changed its name to Lite Strategy, Inc. in September 2025. Lite Strategy, Inc. was incorporated in 2000 and is based in San Diego, California.
2-Year Price History
Quarterly Financials & Projections
| Period | Rev | EBITDA | OpIn | NI | OCF | FCF | CapEx | Cash | Debt | Shares | ROIC | IntCov | EV/EBITDA | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Act | 2026-Q3 | 0.0 | -2.8 | -2.8 | -23.7 | -1.5 | -1.5 | -0.0 | 7.5 | 0.0 | 6.7 | -25.9% | -- | -- |
| Act | 2026-Q2 | 0.0 | -3.4 | -3.4 | -30.8 | -1.9 | -1.9 | -0.0 | 8.8 | 0.0 | 6.7 | -19.5% | -- | -- |
| Act | 2026-Q1 | 0.0 | -3.1 | -3.7 | -3.6 | -4.5 | -4.5 | -0.0 | 10.1 | 0.0 | 6.7 | -14.8% | -- | -- |
| Act | 2025-Q4 | 0.0 | -2.9 | -2.9 | -2.7 | -2.5 | -2.5 | -0.0 | 18.0 | 0.0 | 6.7 | -209.3% | -- | -- |
Multiples vs the company's own history — cheap or rich relative to itself? Historical fiscal years, then TTM, then forward projections (E). Forward rows hold today's price against projected earnings, so the multiple compresses if the company grows into it.
| Year | Price | Rev Gr | EBITDA % | EBITDA | EV/EBITDA | EV/FCF | P/E | P/S |
|---|---|---|---|---|---|---|---|---|
| TTM | 1.01 | — | — | -12 | 0.0× | 0.0× | 0.0× | — |
EBITDA in reporting-currency $M. Historical multiples use year-end market cap (split-adjusted price history); TTM & forward years use today's.
Valuation & Metrics
Market Stats
TTM Financial Snapshot
Forward Outlook & Risk
Short Interest
Employees
Cash Runway
Institutional Ownership
Headline & net flow
Ownership composition
Top holders
| Fund | $ value | Cost basis | Δ QoQ | Δ YoY | α life | Fund AUM |
|---|---|---|---|---|---|---|
| RENAISSANCE TECHNOLOGIES LLC | $2.0M | $1.90 | +$236K | +$1.9M | +1.2% | $63.91B |
| VANGUARD CAPITAL MANAGEMENT LLCPassive | $1.2M | $1.16 | +$1.2M | +$1.2M | — | $4.04T |
| CITADEL ADVISORS LLC | $847K | $2.42 | −$752K | +$804K | -0.4% | $138.22B |
| TWO SIGMA INVESTMENTS, LP | $713K | $1.60 | −$50K | +$713K | -0.9% | $117.03B |
| GEODE CAPITAL MANAGEMENT, LLCPassive | $466K | $1.85 | +$81K | +$399K | +2.3% | $1.61T |
| MARSHALL WACE, LLP | $387K | $1.42 | −$494K | +$387K | +0.6% | $92.71B |
| VANGUARD FIDUCIARY TRUST COPassive | $225K | $1.16 | +$225K | +$225K | — | $395.83B |
| BlackRock, Inc.Passive | $183K | $2.42 | +$0 | +$106K | -0.2% | $5.69T |
| XTX Topco Ltd | $158K | $1.84 | +$29K | +$158K | -1.9% | $5.74B |
| STATE STREET CORPPassive | $133K | $2.42 | +$0 | +$113K | -0.2% | $2.89T |
| NORTHERN TRUST CORPPassive | $93K | $2.22 | +$0 | +$81K | -0.2% | $755.34B |
| MORGAN STANLEY | $83K | $1.47 | −$0 | +$76K | -0.3% | $1.65T |
| ADAR1 Capital Management, LLC | $78K | $2.42 | +$0 | +$78K | +8.3% | $1.64B |
| JANE STREET GROUP, LLCMM | $66K | $1.85 | −$109K | +$66K | -0.1% | $92.10B |
| UBS Group AG | $60K | $2.42 | −$85K | +$52K | -0.3% | $562.11B |
| NOMURA ASSET MANAGEMENT INTERNATIONAL INC. | $35K | $1.32 | +$0 | +$35K | +1.4% | $58.02B |
| GROUP ONE TRADING LLCMM | $27K | $2.42 | −$4K | +$26K | -1.6% | $3.02B |
| Vanguard Global Advisers, LLCPassive | $21K | $1.16 | +$21K | +$21K | — | $186.48B |
| SUSQUEHANNA INTERNATIONAL GROUP, LLPMM | $19K | $2.42 | −$75K | −$3K | -0.6% | $77.14B |
| Bank Julius Baer & Co. Ltd, Zurich | $3K | $1.16 | +$3K | +$3K | +0.1% | $33.15B |
Trading behavior
▸ Compare to holder-profile behavior (across all their stocks)
Biggest decreases this quarter
New buyers this quarter
Top-5 holders · 77.0%
Top Holders Over Time
5-year share-count history (top 10 holders by peak, incl. exited) + price
Corporate
Insider Trading (last 12mo)
| Date | Side | Insider | Title | Shares | Price | Dollars | Owned $ |
|---|---|---|---|---|---|---|---|
| 2025-12-19 | BUY | Flynn James P | director | 70,000 | $1.40 | $98K | $140K |
| 2025-12-18 | SELL | Schornstein Alexander | 10 percent owner | 690,611 | $1.37 | $946K | $5.03M |
| 2025-11-19 | BUY | Flynn James P | director | 12,100 | $1.88 | $23K | $56K |